4D Molecular Therapeutics, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
4D Molecular Therapeutics, Inc. (FDMT) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $54.50 million as of 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2025-02-28
- 2024-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $54.50M.
- 2023-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $55.00M.
- 2022-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $37.10M.
- 2021-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $37.70M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2024-12-31 | $54.50M 10-K · filed 2025-02-28 |
| 2023-12-31 | $55.00M 10-K · filed 2024-02-29 |
| 2022-12-31 | $37.10M 10-K · filed 2023-03-15 |
| 2021-12-31 | $37.70M 10-K · filed 2022-03-28 |
| 2020-12-31 | $19.40M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |